Tag : ADVANCED RENAL CELL CARCINOMA

CONFERENCE UPDATE

Lenvatinib + pembrolizumab delivers sustained efficacy in aRCC regardless of baseline bone metastases: Final analysis from CLEAR
Bone metastases occur in approximately one-third of patients with advanced renal cell carcinoma and are associated with poor prognosis. This is partly due to RCC-driven immune dysregulation and the release of factors such as fibroblast growth factor and platelet-derived growth factor that promote osteoclast activation and bone resorption.

Professor Camillo Porta

Chairman, Department of Oncology, University of Bari Aldo Moro & Policlinico Consorziale, Bari, Italy
NEWS AND PERSPECTIVE

Nivolumab + ipilimumab demonstrates long-term survival benefits as a first-line treatment for patients with previously untreated advanced renal cell carcinoma
With a median follow-up of 99.1 months, the recent analysis of the CheckMate 214 trial serves as the longest reported follow-up for any phase 3 trial of a checkpoint inhibitor combination therapy in advanced renal cell carcinoma (aRCC), which demonstrated the remarkable and durable clinical responses of nivolumab + ipilimumab as a first-line therapy for untreated aRCC.